Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Ian Judson MD

Ian Judson MD

Ian Judson is Professor of Cancer Pharmacology at The Institute of Cancer Research and Head of the Sarcoma Unit, Royal Marsden Hospital. He trained at Cambridge University, and King’s College Hospital Medical School, London. He carried out research for his MD at The Institute of Cancer Research (ICR) and trained in medical oncology at the Royal Marsden Hospital (RMH) where he was appointed Senior Lecturer in 1989. His principal research interests are new anticancer drug development and the management of soft tissue sarcomas. He has conducted many early clinical trials of new anticancer agents, with an emphasis on pharmacodynamic biomarker studies, including functional imaging. These included trials with a number of licensed products such as raltitrexed, temozolomide, abiraterone acetate, imatinib and everolimus.  He has been treating sarcomas for over 20 years and has a particular interest in the management of gastrointestinal stromal tumours (GIST), having been involved in research into the role of tyrosine kinase inhibitors (TKIs) since the inception of studies with imatinib in 2000. He has published over 215 research papers and numerous reviews and case reports involving new anticancer drug development and the management of soft tissue sarcomas.  He is currently President of the British Sarcoma Group and Treasurer of the EORTC Soft Tissue and Bone Sarcoma Group.

Recent Contributions to PracticeUpdate:

  1. Intensified Doxorubicin Plus Ifosfamide in Soft-Tissue Sarcoma